2,126 results on '"Zile, Michael"'
Search Results
152. Abstract P2051: Incomplete Regression And Persistence Of Interstitial Fibrosis Following Removal Of Left Ventricular Pressure Overload
153. And the band played on: persistent fibrosis after unbanding reveals sex-dependent differences in rats
154. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
155. Mechanisms that limit regression of myocardial fibrosis following removal of left ventricular pressure overload
156. Myocardial fibroblast–matrix interactions and potential therapeutic targets
157. Abstract 17434: Insulin-Like Growth Factor Binding Protein-7 as a Biomarker of Diastolic Dysfunction: Results From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study
158. Abstract 16903: Circulating Growth Differentiation Factor 15 (GDF-15) in Patients With Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF
159. Abstract 14204: Heart Failure With Preserved Ejection Fraction in the Young
160. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy
161. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation
162. Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM‐HF and ATMOSPHERE.
163. Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers
164. Patterns Of Recurrent Heart Failure Hospitalizations In Relation To Cardiovascular Death In Heart Failure With Reduced Ejection Fraction
165. Renin-Angiotensin Inhibition in Diastolic Heart Failure and Chronic Kidney Disease
166. Assessment of Left Ventricular Diastolic Function in Mice
167. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
168. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF
169. Angiotensin‐neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
170. Additional file 1 of Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
171. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
172. Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure
173. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
174. Integrin-Dependent and -Independent Signaling During Pressure-Overload Cardiac Hypertrophy
175. In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the HF-ACTION Randomized Controlled Trial)
176. Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates
177. Changes in Plasma Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of MMPs in Stress-Induced Cardiomyopathy
178. 58 - Devices for Monitoring and Managing Heart Failure
179. The Heart Failure Society of America in 2020: A Vision for the Future
180. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic
181. Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF
182. Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure
183. Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF
184. Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial
185. Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial
186. Left Ventricular Structural Remodeling in Health and Disease: With Special Emphasis on Volume, Mass, and Geometry
187. Chronic Baroreflex Activation: A Potential Therapeutic Approach to Heart Failure With Preserved Ejection Fraction
188. Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 2—Use in Automated Detection
189. Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 1—Insights into Pathophysiology
190. Natural History of Concentric Left Ventricular Geometry in Community-Dwelling Older Adults Without Heart Failure During Seven Years of Follow-Up
191. Left Ventricular Diastolic Function and Exercise Capacity in Community-Dwelling Adults ≥65 Years of Age Without Heart Failure
192. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
193. Abstract 12357: Discordant Mechanisms in Hypertrophy and Heart Failure
194. Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction
195. TCT-281 Reasons for Less Than Maximal Target Doses of Heart Failure Medications in Patients Enrolled in the COAPT Trial
196. Diastolic Dysfunction in Tachycardia-Induced Heart Failure
197. Treatment effects of sacubitril/valsartan compared with valsartan in patients with recent hospitalization
198. Effect of sacubitril/valsartan versus enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
199. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
200. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.